{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:12:56Z","timestamp":1790017976425,"version":"4.0.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3DA041146"],"award-info":[{"award-number":["UH3DA041146"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F32DA047026"],"award-info":[{"award-number":["F32DA047026"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s40263-020-00722-8","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T12:04:07Z","timestamp":1586001847000},"page":"449-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7139-3273","authenticated-orcid":false,"given":"E. Andrew","family":"Townsend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-5246","authenticated-orcid":false,"given":"Matthew L.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"722_CR1","volume-title":"World drug report","author":"United Nations","year":"2019","unstructured":"United Nations. World drug report. Geneva: United Nations; 2019."},{"issue":"1","key":"722_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","volume":"87","author":"J Bell","year":"2020","unstructured":"Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82\u20138.","journal-title":"Biol Psychiatry."},{"key":"722_CR3","doi-asserted-by":"publisher","DOI":"10.17226\/25310","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019","unstructured":"National Academies of Sciences, Engineering, and Medicine. 2019.\u00a0Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press. https:\/\/doi.org\/10.17226\/25310."},{"issue":"3","key":"722_CR4","first-page":"23","volume":"10","author":"G Herget","year":"2005","unstructured":"Herget G. Methadone and buprenorphine added to the WHO list of essential medicines. HIV AIDS Policy Law Rev. 2005;10(3):23\u20134.","journal-title":"HIV AIDS Policy Law Rev."},{"key":"722_CR5","doi-asserted-by":"crossref","unstructured":"Wightman RS, Nelson LS, Lee JD, Fox LM, Smith SW. Severe opioid withdrawal precipitated by Vivitrol\u00ae. Am J Emerg Med. 2018;36(6):1128e1\u20132.","DOI":"10.1016\/j.ajem.2018.03.052"},{"issue":"2","key":"722_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/add.14735","volume":"115","author":"EV Nunes","year":"2020","unstructured":"Nunes EV, Bisaga A, Krupitsky E, Nangia N, Silverman BL, Akerman SC, et al. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. Addiction. 2020;115(2):239\u201346.","journal-title":"Addiction."},{"key":"722_CR7","doi-asserted-by":"publisher","first-page":"107574","DOI":"10.1016\/j.drugalcdep.2019.107574","volume":"204","author":"R Daniulaityte","year":"2019","unstructured":"Daniulaityte R, Nahhas RW, Silverstein S, Martins S, Zaragoza A, Moeller A, et al. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: a latent class analysis. Drug Alcohol Depend. 2019;204:107574.","journal-title":"Drug Alcohol Depend."},{"issue":"26","key":"722_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.15585\/mmwr.mm6526a2","volume":"65","author":"CM Jones","year":"2016","unstructured":"Jones CM, Baldwin GT, Manocchio T, White JO, Mack KA. Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths\u2014United States, 2002\u20132014. MMWR Morb Mortal Wkly Rep. 2016;65(26):667\u201371.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"2","key":"722_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1124\/jpet.105.095380","volume":"317","author":"SS Negus","year":"2006","unstructured":"Negus SS. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone. J Pharmacol Exp Ther. 2006;317(2):711\u201323.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"722_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1124\/pr.117.013904","volume":"69","author":"PT Bremer","year":"2017","unstructured":"Bremer PT, Janda KD. Conjugate vaccine immunotherapy for substance use disorder. Pharmacol Rev. 2017;69(3):298\u2013315.","journal-title":"Pharmacol Rev."},{"key":"722_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.irn.2016.02.009","volume":"126","author":"O Ohia-Nwoko","year":"2016","unstructured":"Ohia-Nwoko O, Kosten TA, Haile CN. Animal models and the development of vaccines to treat substance use disorders. Int Rev Neurobiol. 2016;126:263\u201391.","journal-title":"Int Rev Neurobiol."},{"issue":"11","key":"722_CR12","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","volume":"39","author":"ML Banks","year":"2018","unstructured":"Banks ML, Olson ME, Janda KD. Immunopharmacotherapies for treating opioid use disorder. Trends Pharmacol Sci. 2018;39(11):908\u201311.","journal-title":"Trends Pharmacol Sci."},{"issue":"2","key":"722_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","volume":"12","author":"S Johnson","year":"1992","unstructured":"Johnson S, North R. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12(2):483\u20138.","journal-title":"J Neurosci."},{"key":"722_CR14","doi-asserted-by":"publisher","first-page":"e39945","DOI":"10.7554\/eLife.39945","volume":"7","author":"J Corre","year":"2018","unstructured":"Corre J, van Zessen R, Loureiro M, Patriarchi T, Tian L, Pascoli V, et al. Dopamine neurons projecting to medial shell of the nucleus accumbens drive heroin reinforcement. eLife. 2018;7:e39945.","journal-title":"eLife."},{"key":"722_CR15","first-page":"1336","volume":"2","author":"FS Caruso","year":"1973","unstructured":"Caruso FS, Gordon M, Pachter IJ. Methadone and naloxone in combination (Naldone) for the treatment of heroin addicts. Proc Natl Conf Methadone Treat. 1973;2:1336\u201341.","journal-title":"Proc Natl Conf Methadone Treat."},{"issue":"1","key":"722_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41386-018-0197-3","volume":"44","author":"C Baehr","year":"2019","unstructured":"Baehr C, Pravetoni M. Vaccines to treat opioid use disorders and to reduce opioid overdoses. Neuropsychopharmacology. 2019;44(1):217\u20138.","journal-title":"Neuropsychopharmacology."},{"issue":"3","key":"722_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0160-5402(86)90056-2","volume":"15","author":"LA Dykstra","year":"1986","unstructured":"Dykstra LA, Woods JH. A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J Pharmacol Methods. 1986;15(3):263\u20139.","journal-title":"J Pharmacol Methods."},{"key":"722_CR18","doi-asserted-by":"publisher","first-page":"107730","DOI":"10.1016\/j.neuropharm.2019.107730","volume":"158","author":"RD Tenney","year":"2019","unstructured":"Tenney RD, Blake S, Bremer PT, Zhou B, Hwang CS, Poklis JL, et al. Vaccine blunts fentanyl potency in male rhesus monkeys. Neuropharmacology. 2019;158:107730.","journal-title":"Neuropharmacology."},{"issue":"5492","key":"722_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/253565a0","volume":"253","author":"M Torten","year":"1975","unstructured":"Torten M, Miller CH, Eisele JH, Henderson GL, Benjamini E. Prevention of the effects of fentanyl by immunological means. Nature. 1975;253(5492):565\u20136.","journal-title":"Nature."},{"issue":"3","key":"722_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","volume":"199","author":"M Haney","year":"2008","unstructured":"Haney M, Spealman R. Controversies in translational research: drug self-administration. Psychopharmacology. 2008;199(3):403\u201319.","journal-title":"Psychopharmacology."},{"issue":"3","key":"722_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1124\/pr.115.011668","volume":"68","author":"PW Czoty","year":"2016","unstructured":"Czoty PW, Stoops WW, Rush CR. Evaluation of the \u201cpipeline\u201d for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research. Pharmacol Rev. 2016;68(3):533\u201362.","journal-title":"Pharmacol Rev."},{"issue":"6","key":"722_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0893-133X(95)00274-H","volume":"14","author":"NK Mello","year":"1996","unstructured":"Mello NK, Negus SS. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology. 1996;14(6):375\u2013424.","journal-title":"Neuropsychopharmacology."},{"key":"722_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.tips.2016.11.002","volume":"38","author":"ML Banks","year":"2017","unstructured":"Banks ML, Negus SS. Insights from preclinical choice models on treating drug addiction. Trends Pharmacol Sci. 2017;38:181\u201394.","journal-title":"Trends Pharmacol Sci."},{"key":"722_CR24","volume-title":"The behavior of organisms","author":"B Skinner","year":"1938","unstructured":"Skinner B. The behavior of organisms. New York: Appleton-Century-Crofts; 1938."},{"issue":"5485","key":"722_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/252708a0","volume":"252","author":"KF Bonese","year":"1974","unstructured":"Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature. 1974;252(5485):708\u201310.","journal-title":"Nature."},{"issue":"3","key":"722_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/0091-3057(78)90295-2","volume":"9","author":"A Killian","year":"1978","unstructured":"Killian A, Bonese K, Rothberg RM, Wainer BH, Schuster CR. Effects of passive immunization against morphine on heroin self-administration. Pharmacol Biochem Behav. 1978;9(3):347\u201352.","journal-title":"Pharmacol Biochem Behav."},{"issue":"14","key":"722_CR27","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1021\/jm200461m","volume":"54","author":"GN Stowe","year":"2011","unstructured":"Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G, et al. A vaccine strategy that induces protective immunity against heroin. J Med Chem. 2011;54(14):5195\u2013204.","journal-title":"J Med Chem."},{"issue":"3","key":"722_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bph.12305","volume":"170","author":"A Gott\u00e5s","year":"2013","unstructured":"Gott\u00e5s A, \u00d8iestad EL, Boix F, Vindenes V, Ripel \u00c5, Thaulow CH, et al. Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats. Br J Pharmacol. 2013;170(3):546\u201356.","journal-title":"Br J Pharmacol."},{"issue":"25","key":"722_CR29","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.1021\/jacs.7b03334","volume":"139","author":"PT Bremer","year":"2017","unstructured":"Bremer PT, Schlosburg JE, Banks ML, Steele FF, Zhou B, Poklis JL, et al. Development of a clinically viable heroin vaccine. J Am Chem Soc. 2017;139(25):8601\u201311.","journal-title":"J Am Chem Soc."},{"issue":"19","key":"722_CR30","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1056\/NEJM198405103101902","volume":"310","author":"CE Inturrisi","year":"1984","unstructured":"Inturrisi CE, Max MB, Foley KM, Schultz M, Shin S-U, Houde RW. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med. 1984;310(19):1213\u20137.","journal-title":"N Engl J Med."},{"issue":"1","key":"722_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/03602537508993748","volume":"4","author":"U Boerner","year":"1975","unstructured":"Boerner U. The metabolism of morphine and heroin in man. Drug Metab Rev. 1975;4(1):39\u201373.","journal-title":"Drug Metab Rev."},{"issue":"7","key":"722_CR32","doi-asserted-by":"publisher","first-page":"e101807","DOI":"10.1371\/journal.pone.0101807","volume":"9","author":"M Pravetoni","year":"2014","unstructured":"Pravetoni M, Pentel PR, Potter DN, Chartoff EH, Tally L, LeSage MG. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS One. 2014;9(7):e101807.","journal-title":"PLoS One."},{"key":"722_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neuropharm.2018.06.026","volume":"138","author":"JD Nguyen","year":"2018","unstructured":"Nguyen JD, Hwang CS, Grant Y, Janda KD, Taffe MA. Prophylactic vaccination protects against the development of oxycodone self-administration. Neuropharmacology. 2018;138:292\u2013303.","journal-title":"Neuropharmacology."},{"issue":"12","key":"722_CR34","doi-asserted-by":"publisher","first-page":"e115696","DOI":"10.1371\/journal.pone.0115696","volume":"9","author":"MD Raleigh","year":"2014","unstructured":"Raleigh MD, Pentel PR, LeSage MG. Pharmacokinetic correlates of the effects of a heroin vaccine on heroin self-administration in rats. PLoS One. 2014;9(12):e115696.","journal-title":"PLoS One."},{"issue":"3","key":"722_CR35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0022-3565(25)38246-7","volume":"265","author":"SS Negus","year":"1993","unstructured":"Negus SS, Henriksen SJ, Mattox A, Pasternak GW, Portoghese PS, Takemori AE, et al. Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats. J Pharmacol Exp Ther. 1993;265(3):1245\u201352.","journal-title":"J Pharmacol Exp Ther."},{"issue":"11","key":"722_CR36","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/s41593-018-0246-6","volume":"21","author":"M Venniro","year":"2018","unstructured":"Venniro M, Zhang M, Caprioli D, Hoots JK, Golden SA, Heins C, et al. Volitional social interaction prevents drug addiction in rat models. Nat Neurosci. 2018;21(11):1520\u20139.","journal-title":"Nat Neurosci."},{"issue":"4","key":"722_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/0091-3057(81)90211-2","volume":"15","author":"BK Alexander","year":"1981","unstructured":"Alexander BK, Beyerstein BL, Hadaway PF, Coambs RB. Effect of early and later colony housing on oral ingestion of morphine in rats. Pharmacol Biochem Behav. 1981;15(4):571\u20136.","journal-title":"Pharmacol Biochem Behav."},{"issue":"2","key":"722_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1037\/1064-1297.9.2.131","volume":"9","author":"WJ Lynch","year":"2001","unstructured":"Lynch WJ, Carroll ME. Regulation of drug intake. Exp Clin Psychopharmacol. 2001;9(2):131\u201343.","journal-title":"Exp Clin Psychopharmacol."},{"key":"722_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/9781118023150.ch11","volume-title":"Drug discrimination","author":"SS Negus","year":"2011","unstructured":"Negus SS, Banks ML. Making the right choice: lessons from drug discrimination for research on drug reinforcement and drug self-administration. In: Glennon RA, Young R, editor. Drug discrimination. Hoboken, NJ: Wiley; 2011. p. 361\u201388. https:\/\/doi.org\/10.1002\/9781118023150.ch11."},{"key":"722_CR40","first-page":"281768","volume":"2012","author":"ML Banks","year":"2012","unstructured":"Banks ML, Negus SS. Preclinical determinants of drug choice under concurrent schedules of drug self-administration. Adv Pharmacol Sci. 2012;2012:281768.","journal-title":"Adv Pharmacol Sci."},{"issue":"16","key":"722_CR41","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1016\/j.vaccine.2006.01.047","volume":"24","author":"B Anton","year":"2006","unstructured":"Anton B, Leff P. A novel bivalent morphine\/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine. 2006;24(16):3232\u201340.","journal-title":"Vaccine."},{"issue":"3483","key":"722_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1126\/science.134.3483.943","volume":"134","author":"W Hodos","year":"1961","unstructured":"Hodos W. Progressive ratio as a measure of reward strength. Science. 1961;134(3483):943\u20134.","journal-title":"Science."},{"issue":"1","key":"722_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","volume":"66","author":"NR Richardson","year":"1996","unstructured":"Richardson NR, Roberts DC. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods. 1996;66(1):1\u201311.","journal-title":"J Neurosci Methods."},{"issue":"22","key":"722_CR44","doi-asserted-by":"publisher","first-page":"9036","DOI":"10.1073\/pnas.1219159110","volume":"110","author":"JE Schlosburg","year":"2013","unstructured":"Schlosburg JE, Vendruscolo LF, Bremer PT, Lockner JW, Wade CL, Nunes AA, et al. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci USA. 2013;110(22):9036\u201341.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"722_CR45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/02791072.2018.1508789","volume":"50","author":"JD Jones","year":"2018","unstructured":"Jones JD, Bisaga A, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, et al. The PPARgamma agonist pioglitazone fails to alter the abuse potential of heroin, but does reduce heroin craving and anxiety. J Psychoact Drugs. 2018;50(5):390\u2013401.","journal-title":"J Psychoact Drugs."},{"key":"722_CR46","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000302","author":"JA Lile","year":"2019","unstructured":"Lile JA, Johnson AR, Banks ML, Hatton KW, Hays LR, Nicholson KL, et al. Pharmacological validation of a translational model of cocaine use disorder: effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys. Exp Clin Psychopharmacol. 2019. https:\/\/doi.org\/10.1037\/pha0000302(Epub ahead of print).","journal-title":"Exp Clin Psychopharmacol"},{"issue":"10","key":"722_CR47","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41386-019-0385-9","volume":"44","author":"EA Townsend","year":"2019","unstructured":"Townsend EA, Blake S, Faunce KE, Hwang CS, Natori Y, Zhou B, et al. Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats. Neuropsychopharmacology. 2019;44(10):1681\u20139.","journal-title":"Neuropsychopharmacology."},{"key":"722_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neuropharm.2019.03.019","volume":"151","author":"EB Towers","year":"2019","unstructured":"Towers EB, Tunstall BJ, McCracken ML, Vendruscolo LF, Koob GF. Male and female mice develop escalation of heroin intake and dependence following extended access. Neuropharmacology. 2019;151:189\u201394.","journal-title":"Neuropharmacology."},{"issue":"12","key":"722_CR49","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/sj.npp.1301008","volume":"31","author":"SA Chen","year":"2006","unstructured":"Chen SA, O\u2019Dell LE, Hoefer ME, Greenwell TN, Zorrilla EP, Koob GF. Unlimited access to heroin self-administration: independent motivational markers of opiate dependence. Neuropsychopharmacology. 2006;31(12):2692\u2013707.","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"722_CR50","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/npp.2014.188","volume":"40","author":"CL Wade","year":"2015","unstructured":"Wade CL, Vendruscolo LF, Schlosburg JE, Hernandez DO, Koob GF. Compulsive-like responding for opioid analgesics in rats with extended access. Neuropsychopharmacology. 2015;40(2):421\u20138.","journal-title":"Neuropsychopharmacology."},{"issue":"4","key":"722_CR51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0893-133X(99)00133-5","volume":"22","author":"SH Ahmed","year":"2000","unstructured":"Ahmed SH, Walker JR, Koob GF. Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology. 2000;22(4):413\u201321.","journal-title":"Neuropsychopharmacology."},{"issue":"4","key":"722_CR52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R","volume":"27","author":"WA Hunt","year":"1971","unstructured":"Hunt WA, Barnett LW, Branch LG. Relapse rates in addiction programs. J Clin Psychol. 1971;27(4):455\u20136.","journal-title":"J Clin Psychol."},{"key":"722_CR53","unstructured":"US Food and Drug Administration. The voice of the patient: opioid use disorder. Center for Drug Evaluation and Research Patient-focused Drug Development Initiative; 2018.\u00a0https:\/\/www.fda.gov\/media\/124391\/download. Accessed 11 Nov 2019."},{"key":"722_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2595","author":"ND Volkow","year":"2018","unstructured":"Volkow ND, Woodcock J, Compton WM, Throckmorton DC, Skolnick P, Hertz S, et al. Medication development in opioid addiction: meaningful clinical end points. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aan2595.","journal-title":"Sci Transl Med."},{"issue":"3","key":"722_CR55","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41386-018-0234-2","volume":"44","author":"DJ Reiner","year":"2019","unstructured":"Reiner DJ, Fredriksson I, Lofaro OM, Bossert JM, Shaham Y. Relapse to opioid seeking in rat models: behavior, pharmacology and circuits. Neuropsychopharmacology. 2019;44(3):465\u201377.","journal-title":"Neuropsychopharmacology."},{"issue":"6","key":"722_CR56","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/j.1471-4159.2011.07502.x","volume":"119","author":"Q-Q Li","year":"2011","unstructured":"Li Q-Q, Luo Y-X, Sun C-Y, Xue Y-X, Zhu W-L, Shi H-S, et al. A morphine\/heroin vaccine with new hapten design attenuates behavioral effects in rats. J Neurochem. 2011;119(6):1271\u201381.","journal-title":"J Neurochem."},{"key":"722_CR57","doi-asserted-by":"crossref","unstructured":"Li Q-Q, Sun C-Y, Luo Y-X, Xue Y-X, Meng S-Q, Xu L-Z, et al. A conjugate vaccine attenuates morphine- and heroin-induced behavior in rats. Int J Neuropsychopharmacol. 2015;18(5):pii:pyu093.","DOI":"10.1093\/ijnp\/pyu093"},{"issue":"10","key":"722_CR58","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/s41386-019-0418-4","volume":"44","author":"BJ Tunstall","year":"2019","unstructured":"Tunstall BJ, Vendruscolo LF. Utility of fentanyl vaccines: unique challenges posed by preventing opioid overdose and treating opioid use disorder. Neuropsychopharmacology. 2019;44(10):1675\u20136.","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"722_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00213-003-1441-y","volume":"168","author":"JL Katz","year":"2003","unstructured":"Katz JL, Higgins ST. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology. 2003;168(1):21\u201330.","journal-title":"Psychopharmacology."},{"issue":"1","key":"722_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-006-0529-6","volume":"189","author":"DH Epstein","year":"2006","unstructured":"Epstein DH, Preston KL, Stewart J, Shaham Y. Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology. 2006;189(1):1\u201316.","journal-title":"Psychopharmacology."},{"issue":"1\u20132","key":"722_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.03.001","volume":"96","author":"SD Comer","year":"2008","unstructured":"Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, Walsh SL. The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend. 2008;96(1\u20132):1\u201315.","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"722_CR62","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/npp.2011.226","volume":"37","author":"GT Collins","year":"2012","unstructured":"Collins GT, Narasimhan D, Cunningham AR, Zaks ME, Nichols J, Ko M-C, et al. Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacology. 2012;37(5):1092\u2013103.","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"722_CR63","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1369-1600.2011.00424.x","volume":"18","author":"CW Schindler","year":"2013","unstructured":"Schindler CW, Justinova Z, Lafleur D, Woods D, Roschke V, Hallak H, et al. Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys. Addict Biol. 2013;18(1):30\u20139.","journal-title":"Addict Biol."},{"issue":"5\u20136","key":"722_CR64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/00008877-200209000-00019","volume":"13","author":"DE McMillan","year":"2002","unstructured":"McMillan DE, Hardwick WC, Li M, Owens SM. Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav Pharmacol. 2002;13(5\u20136):465\u201373.","journal-title":"Behav Pharmacol."},{"issue":"1","key":"722_CR65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00213-005-0299-6","volume":"185","author":"JR Daniels","year":"2006","unstructured":"Daniels JR, Wessinger WD, Hardwick WC, Li M, Gunnell MG, Hall CJ, et al. Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons. Psychopharmacology. 2006;185(1):36\u201344.","journal-title":"Psychopharmacology."},{"issue":"9","key":"722_CR66","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1038\/npp.2015.64","volume":"40","author":"RI Desai","year":"2015","unstructured":"Desai RI, Bergman J. Effects of the nanoparticle-based vaccine, SEL-068, on nicotine discrimination in squirrel monkeys. Neuropsychopharmacology. 2015;40(9):2207\u201316.","journal-title":"Neuropsychopharmacology."},{"issue":"3\u20134","key":"722_CR67","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0376-8716(85)90061-4","volume":"14","author":"SG Holtzman","year":"1985","unstructured":"Holtzman SG. Drug discrimination studies. Drug Alcohol Depend. 1985;14(3\u20134):263\u201382.","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"722_CR68","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/nprot.2006.167","volume":"1","author":"M Solinas","year":"2006","unstructured":"Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc. 2006;1(3):1194\u2013206.","journal-title":"Nat Protoc."},{"issue":"1","key":"722_CR69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-3565(25)30571-9","volume":"198","author":"HE Shannon","year":"1976","unstructured":"Shannon HE, Holtzman SG. Evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther. 1976;198(1):54\u201365.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3\u20134","key":"722_CR70","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1369-1600.2007.00070.x","volume":"12","author":"TM Tzschentke","year":"2007","unstructured":"Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol. 2007;12(3\u20134):227\u2013462.","journal-title":"Addict Biol."},{"key":"722_CR71","volume-title":"Conditioned reflexes; an investigation of the physiological activity of the cerebral cortex","author":"IP Pavlov","year":"1927","unstructured":"Pavlov IP, Anrep GV. Conditioned reflexes; an investigation of the physiological activity of the cerebral cortex. London: Oxford University Press, Humphrey Milford; 1927."},{"issue":"9 Pt A","key":"722_CR72","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.neubiorev.2013.05.002","volume":"37","author":"TC Napier","year":"2013","unstructured":"Napier TC, Herrold AA, de Wit H. Using conditioned place preference to identify relapse prevention medications. Neurosci Biobehav Rev. 2013;37(9 Pt A):2081\u20136.","journal-title":"Neurosci Biobehav Rev."},{"key":"722_CR73","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pnpbp.2013.05.012","volume":"45","author":"TA Kosten","year":"2013","unstructured":"Kosten TA, Shen XY, O\u2019Malley PW, Kinsey BM, Lykissa ED, Orson FM, et al. A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:223\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"3","key":"722_CR74","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s00213-005-0022-7","volume":"181","author":"MC Olmstead","year":"2005","unstructured":"Olmstead MC, Burns LH. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology. 2005;181(3):576\u201381.","journal-title":"Psychopharmacology."},{"issue":"3","key":"722_CR75","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0091-3057(90)90007-5","volume":"37","author":"EJ Bilsky","year":"1990","unstructured":"Bilsky EJ, Marglin SH, Reid LD. Using antagonists to assess neurochemical coding of a drug\u2019s ability to establish a conditioned place preference. Pharmacol Biochem Behav. 1990;37(3):425\u201331.","journal-title":"Pharmacol Biochem Behav."},{"issue":"11","key":"722_CR76","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14760584.2017.1378577","volume":"16","author":"RD Heekin","year":"2017","unstructured":"Heekin RD, Shorter D, Kosten TR. Current status and future prospects for the development of substance abuse vaccines. Exp Rev Vaccines. 2017;16(11):1067\u201377.","journal-title":"Exp Rev Vaccines."},{"issue":"10","key":"722_CR77","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tips.2015.07.002","volume":"36","author":"P Skolnick","year":"2015","unstructured":"Skolnick P. Biologic approaches to treat substance-use disorders. Trends Pharmacol Sci. 2015;36(10):628\u201335.","journal-title":"Trends Pharmacol Sci."},{"key":"722_CR78","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drugalcdep.2016.10.017","volume":"169","author":"S Lake","year":"2016","unstructured":"Lake S, Milloy MJ, Dong H, Hayashi K, Wood E, Kerr T, et al. Initiation into prescription opioid injection and associated trends in heroin use among people who use illicit drugs. Drug Alcohol Depend. 2016;169:73\u20139.","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"722_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13011-017-0137-y","volume":"13","author":"LB Monico","year":"2018","unstructured":"Monico LB, Mitchell SG. Patient perspectives of transitioning from prescription opioids to heroin and the role of route of administration. Subst Abuse Treat Prev Policy. 2018;13(1):4.","journal-title":"Subst Abuse Treat Prev Policy."},{"issue":"2","key":"722_CR80","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.117.247049","volume":"365","author":"MD Raleigh","year":"2018","unstructured":"Raleigh MD, Laudenbach M, Baruffaldi F, Peterson SJ, Roslawski MJ, Birnbaum AK, et al. Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats. J Pharmacol Exp Ther. 2018;365(2):346\u201353.","journal-title":"J Pharmacol Exp Ther."},{"key":"722_CR81","doi-asserted-by":"publisher","first-page":"107501","DOI":"10.1016\/j.drugalcdep.2019.06.006","volume":"204","author":"KL Schwienteck","year":"2019","unstructured":"Schwienteck KL, Blake S, Bremer PT, Poklis JL, Townsend EA, Negus SS, et al. Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: comparison with naltrexone. Drug Alcohol Depend. 2019;204:107501.","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"722_CR82","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1021\/acs.jmedchem.7b01427","volume":"61","author":"A Sulima","year":"2018","unstructured":"Sulima A, Jalah R, Antoline JFG, Torres OB, Imler GH, Deschamps JR, et al. A stable heroin analogue that can serve as a vaccine hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse. J Med Chem. 2018;61(1):329\u201343.","journal-title":"J Med Chem."},{"issue":"1","key":"722_CR83","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00213-006-0509-x","volume":"189","author":"MA Sullivan","year":"2006","unstructured":"Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology. 2006;189(1):37\u201346.","journal-title":"Psychopharmacology."},{"issue":"4","key":"722_CR84","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s002130100727","volume":"155","author":"SD Comer","year":"2001","unstructured":"Comer SD, Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW. Effects of repeated oral methamphetamine administration in humans. Psychopharmacology. 2001;155(4):397\u2013404.","journal-title":"Psychopharmacology."},{"issue":"4","key":"722_CR85","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s00213-005-0023-6","volume":"181","author":"SD Comer","year":"2005","unstructured":"Comer SD, Walker EA, Collins ED. Buprenorphine\/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology. 2005;181(4):664\u201375.","journal-title":"Psychopharmacology."},{"issue":"4","key":"722_CR86","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00213-001-0975-0","volume":"160","author":"MK Greenwald","year":"2002","unstructured":"Greenwald MK, Schuh KJ, Hopper JA, Schuster CR, Johanson C-E. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology. 2002;160(4):344\u201352.","journal-title":"Psychopharmacology."},{"key":"722_CR87","doi-asserted-by":"publisher","first-page":"107848","DOI":"10.1016\/j.drugalcdep.2020.107848","volume":"208","author":"EA Townsend","year":"2020","unstructured":"Townsend EA, Negus SS, Poklis JL, Banks ML. Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys. Drug Alcohol Depend. 2020;208:107848.","journal-title":"Drug Alcohol Depend."},{"key":"722_CR88","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pbb.2016.09.008","volume":"150\u2013151","author":"SM Evans","year":"2016","unstructured":"Evans SM, Foltin RW, Hicks MJ, Rosenberg JB, De BP, Janda KD, et al. Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques. Pharmacol Biochem Behav. 2016;150\u2013151:76\u201386.","journal-title":"Pharmacol Biochem Behav."},{"key":"722_CR89","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuropharm.2019.03.023","volume":"151","author":"NB Varshneya","year":"2019","unstructured":"Varshneya NB, Walentiny DM, Moisa LT, Walker TD, Akinfiresoye LR, Beardsley PM. Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances. Neuropharmacology. 2019;151:171\u20139.","journal-title":"Neuropharmacology."},{"key":"722_CR90","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.neuropharm.2019.02.007","volume":"150","author":"DM Walentiny","year":"2019","unstructured":"Walentiny DM, Moisa LT, Beardsley PM. Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice. Neuropharmacology. 2019;150:210\u20136.","journal-title":"Neuropharmacology."},{"issue":"11","key":"722_CR91","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/anie.201511654","volume":"55","author":"PT Bremer","year":"2016","unstructured":"Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC, Janda KD. Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs. Angew Chem Int Ed. 2016;55(11):3772\u20135.","journal-title":"Angew Chem Int Ed."},{"key":"722_CR92","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.drugpo.2019.08.006","volume":"74","author":"M Buresh","year":"2019","unstructured":"Buresh M, Genberg BL, Astemborski J, Kirk GD, Mehta SH. Recent fentanyl use among people who inject drugs: results from a rapid assessment in Baltimore, Maryland. Int J Drug Policy. 2019;74:41\u20136.","journal-title":"Int J Drug Policy."},{"issue":"6","key":"722_CR93","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1021\/acschemneuro.8b00079","volume":"9","author":"CS Hwang","year":"2018","unstructured":"Hwang CS, Smith LC, Natori Y, Ellis B, Zhou B, Janda KD. Efficacious vaccine against heroin contaminated with fentanyl. ACS Chem Neurosci. 2018;9(6):1269\u201375.","journal-title":"ACS Chem Neurosci."},{"issue":"9","key":"722_CR94","doi-asserted-by":"publisher","first-page":"11537","DOI":"10.1021\/acsomega.8b01478","volume":"3","author":"CS Hwang","year":"2018","unstructured":"Hwang CS, Smith LC, Natori Y, Ellis B, Zhou B, Janda KD. Improved admixture vaccine of fentanyl and heroin hapten immunoconjugates: antinociceptive evaluation of fentanyl-contaminated heroin. ACS Omega. 2018;3(9):11537\u201343.","journal-title":"ACS Omega."},{"key":"722_CR95","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3762\/bjoc.15.100","volume":"15","author":"Y Natori","year":"2019","unstructured":"Natori Y, Hwang CS, Lin L, Smith LC, Zhou B, Janda KD. A chemically contiguous hapten approach for a heroin-fentanyl vaccine. Beilstein J Org Chem. 2019;15:1020\u201331.","journal-title":"Beilstein J Org Chem."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00722-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:09:17Z","timestamp":1744715357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00722-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,4]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["722"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00722-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,4]]},"assertion":[{"value":"4 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Research was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Numbers UH3DA041146 and F32DA047026. The National Institute on Drug Abuse had no role in the study design, collection, analysis or interpretation of the data, and in the writing or decision to submit the manuscript for publication. The content of the article is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"E Andrew Townsend and Matthew L. Banks have no biomedical financial interests or potential conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}